Compare BridgeBio Pharma Inc (BBIO) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Sony Group Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Sony Group Corp trades at $23.46 (market cap $139.99B). The key difference: Sony Group Corp is far larger — about 8.4× BridgeBio Pharma Inc's market cap, and Sony Group Corp pays a 0.67% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SONY | |
|---|---|---|
Market Cap | $16.61B | $139.99B |
Sector | Health | Technology |
52-Week High | $90.17 | $30.26 |
52-Week Low | $47.29 | $19.32 |
Enterprise Value | $18.16B | $137.89B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Sony stock trades at $23.46, up 1.56% with bullish technical indicators and strong analyst support. The company shows solid revenue growth with $12.96T in 2025 sales and improved profitability, though 2026 projections indicate potential margin pressure. Recent catalysts include the record-breaking Spider-Man film performance and a $6.3B joint venture with TSMC for next-generation image sensors, positioning Sony for continued entertainment and technology leadership.
Sony presents a compelling investment case with strong entertainment franchises and technological innovation, though investors should monitor execution risks in the gaming transition and potential margin compression. Wall Street remains overwhelmingly bullish with 11 buy ratings and a 29.75% upside potential, but the stock faces challenges from currency volatility and competitive pressures in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
